VIVUS Inc. (VVUS)

4.32
0.34 8.54
NASDAQ : Health Technology
Prev Close 3.98
Open 4.03
Day Low/High 3.77 / 4.32
52 Wk Low/High 2.15 / 6.41
Volume 198.12K
Avg Volume 78.30K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 42.04M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Next Big Thing in Biotech: Vivus

The Next Big Thing in Biotech: Vivus

Adam Feuerstein, senior columnist for TheStreet, says Vivus is the next big thing in biotech.

Cramer's 'Mad Money' Recap: Pay Attention and Prosper

Cramer's 'Mad Money' Recap: Pay Attention and Prosper

Dozens of companies will report earnings soon and they will forecast the fates of countless others, Cramer said.

Arena Pharma's Weight-Loss Pill Has Few Fans in Japan

Arena Pharma's Weight-Loss Pill Has Few Fans in Japan

The Japanese sell-side community doesn't see Belviq as a blockbuster weight-loss pill.

Vivus Insiders Sell Stock Ahead of Crucial FDA Approval Decision

Vivus Insiders Sell Stock Ahead of Crucial FDA Approval Decision

FDA expected to make approval decision on Vivus' weight-loss pill Qnexa on July 17.

Four Drug Stocks Facing FDA Approval Decisions in July

Four Drug Stocks Facing FDA Approval Decisions in July

Vivus, Amarin, Horizon Pharma and Onyx Pharma are expecting FDA drug approval decisions in July.

Don't Chase ARNA

Don't Chase ARNA

The stock is way too extended to consider buying at current levels.

Arena Pharma: Weight-Loss Drug Approved!

Arena Pharma: Weight-Loss Drug Approved!

U.S. regulators approved Arena's Lorqess, the first weight-loss drug to reach the U.S. market in 13 years.

Biotechs Get Interesting

The sector has been attracting the hot money for a couple weeks.

Arena Pharma: Sell-Side Squawks

Arena Pharma: Sell-Side Squawks

What analysts are saying about the upcoming FDA approval decision for Arena's weight-loss drug lorcaserin.

Vivus and Arena: A Tale of Dueling FDA Panel Minutes

Vivus and Arena: A Tale of Dueling FDA Panel Minutes

Check out the similarities and differences in the way FDA summarized FDA panels for Arena Pharma and Vivus.

Arena Pharma And The Fat Lady's Song

Arena Pharma And The Fat Lady's Song

Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.

Biotech Stock Mailbag: Osiris, Arena, Ampio

Biotech Stock Mailbag: Osiris, Arena, Ampio

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Vivus, Arena Obesity Drugs Will Be Approved, Investors Say

Vivus, Arena Obesity Drugs Will Be Approved, Investors Say

TheStreet's FDA Drug Approval Contest attracts record number of entries, provides accurate predictor for future FDA actions.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who can best guess the outcomes of this summer's hottest FDA events?

Arena Trading Surges Ahead of Key FDA Drug Approval Decision

Arena Trading Surges Ahead of Key FDA Drug Approval Decision

Arena share price and volume are exploding higher as investors wait for FDA to rule on the company's weight-loss drug.

Cramer's 'Mad Money' Recap: Europe's Problems Difficult but Can Be Solved

Cramer's 'Mad Money' Recap: Europe's Problems Difficult but Can Be Solved

Cramer said a favorable resolution could give markets a 10% pop.

Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer

Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Slow, but Positive

The longer this action persists, the more anxious folks will be to put idle cash to work.

Outlooks for Pfizer, Arena and Onyx Following Busy May

Outlooks for Pfizer, Arena and Onyx Following Busy May

Healthcare investor Nate Sadeghi says Pfizer's arthritis drug and Arena's obesity drug will be approved, while confidence in Onyx's cancer drug has increased.

Renting, Not Buying

I'm playing the bounce and taking on a few trades.

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

A closer look at 13F regulatory filings in the biotech sector for the first quarter.

Mulling Arena Pharma's Future With Obesity Drug on Approval Path

Mulling Arena Pharma's Future With Obesity Drug on Approval Path

Thoughts and questions following last week's positive FDA panel for Arena's weight-loss drug lorcaserin.

Cramer: Arena Is a Lottery Ticket That Paid Off

Cramer: Arena Is a Lottery Ticket That Paid Off

Jim Cramer explains it's important for smaller companies to have the opportunity to come up with solutions to dreaded diseases like obesity.

Arena Pharma: FDA Panel Live Blog

Arena Pharma: FDA Panel Live Blog

Join TheStreet biotech columnist Adam Feuerstein as he provides live coverage of the FDA advisory panel reviewing Arena Pharma's obesity drug lorcaserin.

Biotech Stock Mailbag: Exelixis, Protalix, Arena

Biotech Stock Mailbag: Exelixis, Protalix, Arena

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

29 Drugs Facing FDA Approval in 2012

29 Drugs Facing FDA Approval in 2012

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.

Arena: FDA Adds Obesity Docs to Panel

Arena: FDA Adds Obesity Docs to Panel

Getting ready for the May 10 FDA advisory panel reviewing Arena's obesity drug lorcaserin.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Arena Pharma's Own Data Point to Weight-Loss Drug Rejection

Arena Pharma's Own Data Point to Weight-Loss Drug Rejection

More reasons to doubt Arena's ability to convince FDA to approve its obesity drug lorcaserin.

'Mad Money' Lightning Round: Broadcom In, Vivus Out

'Mad Money' Lightning Round: Broadcom In, Vivus Out

In the Lightning Round, Cramer was bullish on MON, HEK, BRCM and OC, bearish on VVUS and a few others.

TheStreet Quant Rating: D (Sell)